Abstract 1726
Background
Ramucirumab (RAM) with weekly paclitaxel (wPTX) is the recommended standard second-line therapy for advanced and recurrent gastric cancer (GC). In a recent phase II study, wNab-PTX + RAM combination for GC showed promising safety and efficacy, but it remains unclear whether wPTX + RAM or wNab-PTX + RAM should be used as second-line therapy. The previous ABSOLUTE Trial compared triweekly Nab-PTX, wNab-PTX, and wPTX in patients with advanced/recurrent GC as second-line therapy. Subgroup analysis of subjects with peritoneal dissemination (52.8%) showed that the hazard ratios (HRs) for overall survival (OS) and progression-free survival (PFS) in the wNab-PTX arm compared with the wPTX arm were 0.78 and 0.64, respectively. Therefore, we are investigating whether wNab-PTX + RAM is more effective than wPTX + RAM for patients with peritoneal dissemination.
Trial design
WJOG10617G/P-SELECT is an open-label, randomized, phase II study evaluating wPTX + RAM (arm A) versus wNab-PTX + RAM (arm B). Key eligibility criteria: 1) Histological diagnosis of primary GC, 2) unresectable or recurrent GC, 3) patients with peritoneal dissemination, 4) intolerant or refractory to first-line therapy including a fluoropyrimidine, and 5) ECOG Performance Status (PS) 0-2. Stratification factors are: institution, PS, and severity of ascites. Arm A comprises PTX 80 mg/m2(day 1,8,15) and RAM 8 mg/kg (day 1,15) every 4 weeks. Arm B comprises Nab-PTX 100 mg/m2(day 1,8,15) instead of PTX. The primary endpoint is OS, and the main secondary endpoints are PFS, objective response rate (ORR), safety, and neuropathy-specific quality of life (QOL). SPARC and Caveolin-1 (Cav-1) expression in tumor tissues will be evaluated as predictive biomarkers for efficacy. Pharmacokinetics of RAM will also be assessed. The required sample size for the full analysis was 50 patients per group to maintain a probability of 70% or higher that the HR for OS in arm B would be lower than 0.90. Enrollment was therefore set at 105 subjects. This study has enrolled 26 patients as of March 31, 2019.
Clinical trial identification
jRCTs031180022, 27 September 2018.
Editorial acknowledgement
Legal entity responsible for the study
WJOG (West Japan Oncology Group).
Funding
Taiho Pharmaceutical Co., Ltd.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2674 - Multicenter Phase I Trial of Trastuzumab Emtansine (T-DM1) in Combination with Non-Pegylated Liposomal Doxorubicin (NPLD) in HER2[+] Metastatic Breast Cancer (MBC). THELMA Study
Presenter: Elena López-Miranda
Session: Poster Display session 2
Resources:
Abstract
1398 - Phase 1 study of liposomal formulation of eribulin (E7389-LF) in patients (pts) with advanced solid tumors: primary results of dose-escalation part
Presenter: Noboru Yamamoto
Session: Poster Display session 2
Resources:
Abstract
5818 - Polo-like Kinase 1 inhibitor onvansertib synergizes with paclitaxel in breast cancer carrying p53 mutation
Presenter: Antonio Giordano
Session: Poster Display session 2
Resources:
Abstract
5927 - Phase 1b study of heat shock protein 90 inhibitor, onalespib in combination with paclitaxel in patients with advanced, triple negative breast cancer (NCT02474173).
Presenter: Robert Wesolowski
Session: Poster Display session 2
Resources:
Abstract
1695 - Impact of pertuzumab and T-DM1 on prognosis of HER2-positive metastatic breast cancer (MBC) and factors affecting their efficacy: results from the AGMT_MBC-Registry
Presenter: Simon Peter Gampenrieder
Session: Poster Display session 2
Resources:
Abstract
1742 - Clinical profile and outcome of HER2 positive breast cancer patients with brain metastases treated with HER2 targeted therapy: Real world experience.
Presenter: Prabhat Bhargava
Session: Poster Display session 2
Resources:
Abstract
1846 - Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer: results of single arm phase IV COMACHI study
Presenter: Norikazu Masuda
Session: Poster Display session 2
Resources:
Abstract
5385 - Anti HER-2 Therapies and Left Ventricular Dysfunction The Renaissance Study
Presenter: ANDRES DANIELE
Session: Poster Display session 2
Resources:
Abstract
3320 - Safety and efficacy of T-DM1 in 128 patients with advanced HER2+ breast cancer: The Royal Marsden experience.
Presenter: Nicolò Battisti
Session: Poster Display session 2
Resources:
Abstract
4540 - Use of trastuzumab emtansine (T-DM1; K) after pertuzumab + trastuzumab (PH) in patients with HER2-positive metastatic breast cancer (mBC): challenges in assessing effectiveness of treatment sequencing in the real world (RW)
Presenter: Thibaut Sanglier
Session: Poster Display session 2
Resources:
Abstract